相关实验视频
Updated: Jan 30, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
慢性压力通过脑肝交感轴介导的catecholamine抵抗诱导肝硬化
Shanshan Wu1,2, Jiachen Liu1,2, Shanshan Huang1,2
1Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.
慢性压力通过破坏交感神经信号,导致肝脏脂肪积累 (MASLD). 激活特定受体 (β3-AR) 可能为与压力相关的肝病提供治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 肝病学 肝病学是一种肝病学.
- 内分泌学 在内分泌学.
背景情况:
- 慢性压力与代谢功能障碍相关的脂肪性肝病 (MASLD) 有关.
- 精确的机制连接压力和MASLD还没有完全理解.
- 肝交感内置在新陈代谢调节中起作用.
研究的目的:
- 阐明关联慢性压力与MASLD的神经机制.
- 为了研究肝脏上腺激素信号在压力诱导的肝脏肥胖症中的作用.
- 确定与压力相关的MASLD的潜在治疗点.
主要方法:
- 小鼠接受了慢性克制压力 (CRS).
- 评估了肝硬化症,交感纤维完整性和上腺体信号传递.
- 使用神经回路追踪 (伪狂犬病病毒) 和药理干预 (mirabegron,同情阻塞).
主要成果:
- CRS诱导了体重独立的肝肥胖症和交感纤维退化.
- 压力导致肝脏的甲醇胺耐药性,通过杀β-上腺素/cAMP信号和降低β3-AR的调节.
- 阻断肝交感输入或激活β3-AR与mirabegron改善了压力诱导的肥胖症.
- 一个CeM-CRHPVH的神经通路被确定为介导压力诱导的肝硬化症.
结论:
- 一个CeM-CRHPVH-肝交感轴将中心压力与MASLD中的外周上腺激素脱敏和脂质失调联系起来.
- 肝脏β3-AR信号传递对于缓解压力诱导的脂质积累至关重要.
- 针对这一轴,为与压力相关的MASLD提供了潜在的治疗策略.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
The Sympathetic Nervous System
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Hypothalamic-Pituitary Axis
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

